Phase II study of peptide vaccination for patients with metastatic lung or gastro-intestinal tract cancers

Phase II study of peptide vaccination for patients with metastatic lung or gastro-intestinal tract cancers - Phase II study of peptide vaccination for patients with metastatic cancers

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002857

Enrollment

Registered

2009-12-07

Start date

2008-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer, pharyngeal cancer, gastric cancer, jejunal cancer, ileal cancer, pancreas cancer, biliary tract cancer, soft tissue sarcoma

Interventions

peptide vaccinnation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) clinically and pathologically diagnosed lung cancer, pharyngeal cancer, esophageal cancer, gastric cancer, pancreas cancer, bile duct cancer, intestinal cancer, or colon cancer 2) obtains lesion(s) that can be evaluated by RECIST. 3) refractory for standard therapies 4) Performance status (ECOG) 0 or 1 5) more tha 4 weeks after prior therapy 6) WBC >=3,000 lymphocytes>=1,000 Hb>=9.0 Platelet>=100,000 Serum creatinine<=1.4 Total bilirubin <=1.5 7) obtains written informed consent

Exclusion criteria

Exclusion criteria: 1) HIV positive patients 2) severe comorbidity (respiratory disease, immunological disease, coagulation disorders, etc) 3) pregnant woman

Design outcomes

Primary

Measure	Time frame
Evaluation of efficacy by RECIST criteria	—

Secondary

Measure	Time frame
Overall survival, Responsive rate, TTF, Immunological responses by peptide vaccination (CTL, CD8, regT)	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026